Company Overview and News

 
Xian Leng inks MoU to participate in PR1MA in Kedah

2018-10-16 theedgemarkets
KUALA LUMPUR: Ornamental fish breeder and trader Xian Leng Holdings Bhd will participate in constructing a 500-unit multistorey flat at Ulu Melaka in Langkawi, Kedah under the 1Malaysia People’s Housing Programme (PR1MA).
BSMAF 7121 1818

 
KLCI to stay lacklustre in line with global markets’ decline

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 16): The FBM KLCI is expected to start on a lacklustre note today, in line with the overnight fall at most global markets, as sentiment at the world bourses remains jittery with rising geopolitical tensions amid the simmering US-Sino trade conflict.
7181 6025 7121 0131

 
Ideal United Bintang, Hovid, Aturmaju, KIP REIT, Berjaya Media, Xian Leng, Diversified Gateway and DBE Gurney

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Oct 16) may include Ideal United Bintang International Bhd, Hovid Bhd, Aturmaju Resources Bhd, KiP REIT, Berjaya Media Bhd, Xian Leng Holdings Bhd, Diversified Gateway Solutions Bhd and DBE Gurney Resources Bhd
7181 9687 6025 7121 0131

 
Xian Leng inks MoU to participate in People's Housing Programme in Kedah

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): Ornamental fish breeder and trader Xian Leng Holdings Bhd will participate in the construction of a 500-unit multi-storey flat at Ulu Melaka in Langkawi, Kedah under the 1Malaysia People's Housing Programme.
BSMAF 7121 1818

 
Xian Leng's 2Q net loss narrows on improved sales

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Ornamental fish breeder and trader Xian Leng Holdings Bhd posted a lower net loss of RM38,000 in the second quarter ended July 31, 2018, from RM428,000 in the previous year owing to higher sales volume and productivity of Arowana fish.
7121

 
Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): Based on the corporate announcements and news flow today, companies in focus on Thursday (July 5) may include: Serba Dinamik, Xian Leng, SCGM, Perdana Petroleum, TA Global, MNRB, China Automobile Parts and JMR.
4898 7108 6459 5229 7043 5158 BSMAF 7121 1818

 
Lee Kian Hu is new Xian Leng chairman

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): Lee Kian Hu has been redesignated as the independent and non-executive chairman of Xian Leng Holdings Bhd, following the retirement of Augustine TK James today.
BSMAF 7121 1818

 
The Week Ahead: New Cabinet members, PNB chairman and Umno chief

2018-07-02 theedgemarkets
Malaysians will start the week with new members of the Cabinet being sworn in at Istana Negara on Monday (July 2). Before that, Umno will elect a new president over the weekend. Whoever wins the party election will have a big task ahead. He will have to find ways to improve the morale of members and regain the support of voters. The new chief will have to chart a new course for the political party.
8362 7121 0161

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...